Audentes Therapeutics (BOLD) Misses Q3 EPS by 9c

Audentes Therapeutics (NASDAQ: BOLD) reported Q3 EPS of ($0.97), $0.09 worse than the analyst estimate of ($0.88). Revenue for the quarter came in at $0 , versus $0 reported last year.

As of September 30, 2018, we had cash, cash equivalents, marketable securities and restricted cash of $285.5 million, which includes approximately $3.6 million of restricted cash and approximately $1.3 million of long-term investments.

For earnings history and earnings-related data on Audentes Therapeutics (BOLD) click here.

You May Also Be Interested In

• Lockheed Martin stock jumps on earnings beat, raised guidance
• United Bankshares (UBSI) Tops Q2 EPS by 6c
• Union Pacific (UNP) Tops Q2 EPS by 22c